Nucleic Acid Therapeutics

Papers
(The H4-Index of Nucleic Acid Therapeutics is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Combined 20-Hydroxyecdysone and Antisense-Mediated Exon Skipping Improve Functional Outcomes in a Mouse Model of Duchenne Muscular Dystrophy137
SIDT2 Inhibits Phosphorothioate Antisense Oligonucleotide Activity by Regulating Cellular Localization of Lysosomes107
Rat and Rabbit Whole-Embryo Culture as a New Approach Method for Unlabeled Therapeutic Antisense Oligonucleotide Hazard Identification with No Requirement for Microinjection or Assisted Transfection88
Assessing Hybridization-Dependent Off-Target Risk for Therapeutic Oligonucleotides: Updated Industry Recommendations81
Knockdown of Circular RNAs Using LNA-Modified Antisense Oligonucleotides49
Therapeutic siRNA Loaded to RISC as Single and Double Strands Requires an Appropriate Quantitative Assay for RISC PK Assessment48
Correction to: Understanding and Rescuing the Splicing Defect Caused by the Frequent ABCA4 Variant c.4253 + 43G>A Underlyin45
Mechanistic Insights into Hybridization-Based Off-Target Activity of GalNAc-siRNA Conjugates40
Screening Splice-Switching Antisense Oligonucleotides in Pancreas-Cancer Organoids30
Challenges of Assessing Exon 53 Skipping of the Human DMD Transcript with Locked Nucleic Acid-Modified Antisense Oligonucleotides in a Mouse Model for Du25
Inhibition of Epidermal Growth Factor Receptor Signaling by Antisense Oligonucleotides as a Novel Approach to Epidermal Growth Factor Receptor Inhibition20
Quantification of mRNA Decay Rates in HeLa and SH-SY5Y Cell Lines Reveals Novel Properties of Membrane Protein Coding Transcripts20
Design and In Vitro Evaluation of a Novel Antisense Oligonucleotide for Treatment of BK Virus Infection20
Improvements to Hybridization-Ligation ELISA Methods to Overcome Bioanalytical Challenges Posed by Novel Oligonucleotide Therapeutics19
Reversible Aptamer Staining, Sorting, and Cleaning of Cells (Clean FACS) with Antidote Oligonucleotide or Nuclease Yields Fully Responsive Cells19
Sequence- and Structure-Dependent Cytotoxicity of Phosphorothioate and 2′- O -Methyl Modified Single-Stranded Oligonucleotides18
Considerations for the Terminal Sterilization of Oligonucleotide Drug Products18
Cross-Species Translation of Biophase Half-Life and Potency of GalNAc-Conjugated siRNAs17
0.07779598236084